Erika Hamilton

机构：Sarah Cannon Research Institute, Brentwood Hospital, Sarah Cannon, Tennessee Oncology · ORCID：0000-0002-1911-0336

发表论文 844 篇 · 总被引 19029 次 · h-index 61

代表论文

• DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer (2026 · Clinical Cancer Research · 被引 1)
• Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study (2026 · ESMO Open)
• The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer Treatment (2026 · Oncology The American Medical Journal)
• Abstract 3149: Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043 (2026 · Cancer Research)
• Supplementary Data 1 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer (2026)
• Data from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer (2026)